Actively Recruiting
BRAVO Study Evaluating ERVEBO4 Vaccine Effectiveness and Safety Among Frontline Workers During the 2026 Bundibugyo Virus Outbreak in the Democratic Republic of Congo
Led by Epicentre · Updated on 2026-10-29
20000
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
The BRAVO study is a phased research effort conducted during the 2026 Bundibugyo virus disease BVD outbreak in the Democratic Republic of the Congo. It focuses on frontline workers at increased risk of infection due to their roles in patient care and outbreak response. The main purpose is to evaluate the effectiveness and safety of the ERVEBO4 vaccine, which is licensed against Zaire ebolavirus, for potential protection against Bundibugyo virus, while also providing evidence to guide future vaccination strategies. Participants include adults aged 18 years and older working in Ebola treatment centers, healthcare settings, laboratories, or involved in community outbreak activities in affected areas. The study has three phases, with Step A being the current focus a prospective cohort study assessing real-world ERVEBO4 vaccination during the outbreak. Both vaccinated and unvaccinated frontline workers are enrolled to compare outcomes. Vaccination is administered as part of routine outbreak response, and future phases may evaluate other vaccine strategies if available. Participants will be followed for up to six months after enrollment or until the outbreak ends, with pregnant participants monitored through pregnancy outcomes. Data collection includes clinical and laboratory information from Ebola treatment facilities, safety monitoring of serious adverse events within one month after vaccination, and evaluation of vaccine impact on disease incidence, severity, and mortality. The study also aims to strengthen outbreak preparedness through improved vaccination delivery, pharmacovigilance, and communication systems.
CONDITIONS
Brief Title
BRAVO is a Phased Outbreak-response Study in the DRC Evaluating ERVEBO® Vaccination in ~20,000 Frontline Workers During the 2026 BDV Outbreak, Step A Assesses Real-world Effectiveness, Safety, and Impact on Severe Disease and Mortality, While Generating Evidence for Future BDV Vaccination Strategies
Research Team
L
Lise Denoeud
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here